Lipomics Technologies has entered into a two-year collaborative research agreement with Duke University in several key clinical areas to identify pharmacometabolomic markers
Lipomics will provide Duke analytical services for biomarker discovery and validation (using its proprietary platform and technologies relating to lipid profiles) as well as provide data transfer and interpretation services that will streamline the process of biomarker development allowing researchers at Duke easy access to analysis and data.
In return, Lipomics will receive an option to license diagnostic rights on all such markers developed under this agreement through use of Lipomics proprietary technologies.
Initial clinical areas are CNS (schizophrenia and depression) and cardiovascular (response to statins) disorders.
Results from the first project of the collaboration were presented at the Society of Biological Psychiatry meeting in San Diego on 18 May 2007.
The study aimed to define metabolic signatures for patients treated with anti-psychotic drugs.
"We are very excited about this partnership.
"It is a great honour to work with Duke University, one of the leading academic institutions in the country, to advance our clinical diagnostic program" said Meeta Patnaik, chief medical officer of Lipomics.
